A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
Starting soon · Not applicable
Conditions studied: Advanced Gastric Cancer
In brief
To evaluate the efficacy and safety of trifluridine/tipiracil (TAS-102) combined with apatinib as third-line therapy for advanced gastric cancer
Key facts
- Study ID
- NCT07371871
- Run by
- Anhui Provincial Cancer Hospital
- People needed
- 30
- Starts
- 2026-01-08
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2026-01-28
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Gastric cancer confirmed by histopathological or cytological diagnosis;
- unresectable locally advanced or recurrent/metastatic gastric cancer;
- age 18-75 years, regardless of gender;
- ECOG score 0-2;
- previously received second-line treatment for advanced gastric cancer with disease progression during or after treatment;
- at least one measurable lesion present according to RECIST 1.1 criteria;
- laboratory tests meeting the following requirements: (1) Blood routine: HGB≥70g/L; WBC≥4.0×10\^9/L; NEUT≥1.5×10\^9/L; PLT≥90×10\^9/L; (2) Blood biochemistry: ALT, AST≤2.5×upper limit of normal (ULN), serum creatinine≤1.5×upper limit of normal;
- negative pregnancy test for patients of childbearing potential and voluntary use of effective and reliable contraception during the trial.
You may not qualify if…
- Participation in other anti-tumor drug clinical trials within 4 weeks prior to enrollment;
- Any of the following conditions that may interfere with oral medication: inability to swallow, chronic diarrhea, or intestinal obstruction;
- Concurrent receipt of any other systemic anti-tumor therapy (excluding local treatment);
- Previous treatment with VEGFR inhibitors (excluding ramucirumab; pan-targeted TKIs are excluded);
- Known history of allergy to any component of the study drugs;
- Subjects with active infectious diseases;
- Patients deemed unsuitable for enrollment by the investigator due to potential increased study-related risks or possible interference with interpretation of study results, as assessed by the investigator.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.